Title:
SECRETORY IgA AND IgG ANTIBODIES-INDUCING AGENT
Document Type and Number:
WIPO Patent Application WO/2007/032376
Kind Code:
A1
Abstract:
It is intended to provide a nasal vaccine capable of inducing the production of secretory IgA and IgG antibodies which are specific to a Flavivirus such as a Hantavirus. It is also intended to provide a method of preventing infection with a Flavivirus by inducing the secretory IgA and IgG antibodies as described above. Namely, a nasal vaccine whereby favorable secretion of IgA antibody on the nasal mucosa and an IgG antibody response in the serum can be established, characterized in that a vaccine comprising an inactivated antigen originating in a Flavivirus and Poly(I:C) or a ceramic-processed surf clam powder employed as an adjuvant is nasally administered; and a method of inducing IgA and IgG antibodies specific to a Flavivirus characterized by comprising administering an inactivated antigen of a Flavivirus and Poly(I:C) or a ceramic-processed surf clam powder employed as an adjuvant to the mucosa of an respiratory organ.
Inventors:
MORIYAMA MASAMI (JP)
HASEGAWA HIDEKI (JP)
SATA TETSUTAROU (JP)
KURATA TAKESHI (JP)
TANAKA TOSHIAKI (JP)
HASEGAWA HIDEKI (JP)
SATA TETSUTAROU (JP)
KURATA TAKESHI (JP)
TANAKA TOSHIAKI (JP)
Application Number:
PCT/JP2006/318136
Publication Date:
March 22, 2007
Filing Date:
September 13, 2006
Export Citation:
Assignee:
MORIYAMA MASAMI (JP)
HASEGAWA HIDEKI (JP)
SATA TETSUTAROU (JP)
KURATA TAKESHI (JP)
TANAKA TOSHIAKI (JP)
HASEGAWA HIDEKI (JP)
SATA TETSUTAROU (JP)
KURATA TAKESHI (JP)
TANAKA TOSHIAKI (JP)
International Classes:
A61K39/12; A61K39/39; A61P11/00; A61P31/12
Foreign References:
| JPH09206076A | 1997-08-12 | |||
| JP2005314277A | 2005-11-10 | |||
| JP2001026508A | 2001-01-30 |
Other References:
ICHINOHE T. ET AL.: "Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection", JOURNAL OF VIROLOGY, vol. 79, no. 5, 2005, pages 2910 - 2919, XP002424577
WANG L.: "Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination", JOURNAL OF CLINICAL INVESTIGATION, vol. 110, no. 8, 2002, pages 1175 - 1184, XP002971606
ICHINOHE T. ET AL.: "Protection Against Influenza Virus Infection by Intranasal Vaccine with Surf Clam Microparticles (SMP) as an Adjuvant", JOURNAL OF MEDICAL VIROLOGY, vol. 78, 2006, pages 954 - 963, XP003002726
COULTER A.: "Intranasal Vaccination with ISCOMATRIX adjuvanted influenza vaccine", VACCINE, vol. 21, 2003, pages 946 - 949, XP004402622
See also references of EP 1932540A4
WANG L.: "Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination", JOURNAL OF CLINICAL INVESTIGATION, vol. 110, no. 8, 2002, pages 1175 - 1184, XP002971606
ICHINOHE T. ET AL.: "Protection Against Influenza Virus Infection by Intranasal Vaccine with Surf Clam Microparticles (SMP) as an Adjuvant", JOURNAL OF MEDICAL VIROLOGY, vol. 78, 2006, pages 954 - 963, XP003002726
COULTER A.: "Intranasal Vaccination with ISCOMATRIX adjuvanted influenza vaccine", VACCINE, vol. 21, 2003, pages 946 - 949, XP004402622
See also references of EP 1932540A4
Attorney, Agent or Firm:
KUSAMA, Osamu (7F Iwata Bldg., 5-12, Iidabashi 4-chom, Chiyoda-ku Tokyo, JP)
Download PDF:
Previous Patent: PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE α-IONONE
Next Patent: PROCESS FOR PRODUCING QUINONE COMPOUND
Next Patent: PROCESS FOR PRODUCING QUINONE COMPOUND